Thomas Stankovich - Nov 4, 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Nov 4, 2022
Transactions value $
-$2,287
Form type
4
Date filed
11/10/2022, 03:10 PM
Previous filing
Oct 6, 2022
Next filing
Dec 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale -$1.6K -5.88K -1.72% $0.27 335K Nov 4, 2022 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$684 -2.51K -0.75% $0.27 333K Nov 4, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.